{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:24:18Z","timestamp":1791894258624,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,26]]},"DOI":"10.7759\/cureus.93282","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:57:28Z","timestamp":1758895048000},"source":"Crossref","is-referenced-by-count":5,"title":["Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Bryan","family":"Tassavor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Al Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0","article-title":"Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features","volume":"39","author":"Lyseng-Williamson KA","year":"2019","unstructured":"Lyseng-Williamson KA. Glucagon-like peptide-1 receptor analogues in type 2 diabetes: their use and differential features. Clin Drug Investig. 2019, 39:805-19. 10.1007\/s40261-019-00826-0","journal-title":"Clin Drug Investig"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial","volume":"29","author":"Faurschou A","year":"2015","unstructured":"Faurschou A, Gyldenl\u00f8ve M, Rohde U, et al.. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015, 29:555-9. 10.1111\/jdv.12629","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15233","article-title":"The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide","volume":"177","author":"Jennings L","year":"2017","unstructured":"Jennings L, Nestor L, Molloy O, et al.. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017, 177:858-9. 10.1111\/bjd.15233","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu X","year":"2019","unstructured":"Xu X, Lin L, Chen P, et al.. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. Diabetes Res Clin Pract. 2019, 150:167-73. 10.1016\/j.diabres.2019.03.002","journal-title":"Diabetes Res Clin Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0150","article-title":"Liraglutide administration improves hormonal\/metabolic profile and reproductive features in women with HAIR-AN syndrome","volume":"2020","author":"Livadas S","year":"2020","unstructured":"Livadas S, Androulakis I, Angelopoulos N, et al.. Liraglutide administration improves hormonal\/metabolic profile and reproductive features in women with HAIR-AN syndrome. Endocrinol Diabetes Metab Case Rep. 2020, 2020:10.1530\/EDM-19-0150","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-21-0007","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo G","year":"2021","unstructured":"Costanzo G, Curatolo S, Bus\u00e0 B, et al.. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021, 2021:10.1530\/EDM-21-0007","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin L","year":"2022","unstructured":"Lin L, Xu X, Yu Y, et al.. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022, 33:1428-34. 10.1080\/09546634.2020.1826392","journal-title":"J Dermatolog Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.359","article-title":"42762 Successful treatment of hidradenitis suppurativa with semaglutide","volume":"89","author":"Drumm C","year":"2023","unstructured":"Drumm C, Clowry J, Healy M-L, Wynne B. 42762 Successful treatment of hidradenitis suppurativa with semaglutide. J Am Acad Dermatol. 2023, 89:89. 10.1016\/j.jaad.2023.07.359","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.11817\/j.issn.1672-7347.2023.230100","article-title":"Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review","volume":"48","author":"Li R","year":"2023","unstructured":"Li R, Li H, Yang Z, Zhang X. Combination of metformin with liraglutide in treating HAIR-AN syndrome in children: A case report and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023, 48:1425-31. 10.11817\/j.issn.1672-7347.2023.230100","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-23-0017","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos AE","year":"2023","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, et al.. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep. 2023, 2023:10.1530\/EDM-23-0017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.16527","article-title":"The first case of psoriatic skin lesions exacerbation after liraglutide","volume":"133","author":"Nowowiejska J","year":"2023","unstructured":"Nowowiejska J, Baran A, Flisiak I. The first case of psoriatic skin lesions exacerbation after liraglutide. Pol Arch Intern Med. 2023, 133:10.20452\/pamw.16527","journal-title":"Pol Arch Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau J","year":"2023","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, et al.. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023, 161:293-6. 10.1016\/j.medcli.2023.05.021","journal-title":"Med Clin (Barc)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad429","article-title":"Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a\u00a0case\u00a0report","volume":"49","author":"Barry R","year":"2024","unstructured":"Barry R, Murray G, Hellen R, N\u00ed Raghallaigh S. Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a\u00a0case\u00a0report. Clin Exp Dermatol. 2024, 49:409-11. 10.1093\/ced\/llad429","journal-title":"Clin Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.11.007","article-title":"Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa","volume":"162","author":"Nicolau J","year":"2024","unstructured":"Nicolau J, Nadal A, Sanch\u00eds P, et al.. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024, 162:118-22. 10.1016\/j.medcli.2023.11.007","journal-title":"Med Clin (Barc)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59119","article-title":"Acne keloidalis nuchae in a Caucasian non-Hispanic woman with metabolic syndrome and autoimmune thyroiditis: a case report","volume":"16","author":"Anatolieva B","year":"2024","unstructured":"Anatolieva B, Kirov V, Ganeva S. Acne keloidalis nuchae in a Caucasian non-Hispanic woman with metabolic syndrome and autoimmune thyroiditis: a case report. Cureus. 2024, 16:e59119. 10.7759\/cureus.59119","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.06.001","article-title":"Treatment of insulin resistance with tirzepatide leading to improvement of hair loss","volume":"50","author":"Gordon ER","year":"2024","unstructured":"Gordon ER, Musleh S, Bordone LA. Treatment of insulin resistance with tirzepatide leading to improvement of hair loss. JAAD Case Rep. 2024, 50:123-5. 10.1016\/j.jdcr.2024.06.001","journal-title":"JAAD Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.02.023","article-title":"A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide","volume":"52","author":"Chan LJ","year":"2024","unstructured":"Chan LJ, Kaur M, Kaffenberger BH. A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide. JAAD Case Rep. 2024, 52:101-2. 10.1016\/j.jdcr.2024.02.023","journal-title":"JAAD Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76267","article-title":"Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report","volume":"16","author":"Morrissette K","year":"2024","unstructured":"Morrissette K, Hansen S, Pavlis M, Murray JC. Improvement of recalcitrant folliculitis decalvans with tirzepatide: a case report. Cureus. 2024, 16:e76267. 10.7759\/cureus.76267","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.11.039","article-title":"Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX","volume":"92","author":"Hill MA","year":"2025","unstructured":"Hill MA, Bordeaux JS. Semaglutide use for decreasing hidradenitis suppurativa resource utilization: A retrospective cohort study utilizing TriNetX. J Am Acad Dermatol. 2025, 92:896-7. 10.1016\/j.jaad.2024.11.039","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20392","article-title":"Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa","volume":"39","author":"Posada Posada MI","year":"2025","unstructured":"Posada Posada MI, Alora MB, Lima XT. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025, 39:e662-4. 10.1111\/jdv.20392","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107 J","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107 J, Bini\u0107 I, Cari\u0107 B, et al.. Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025, 15:10.3390\/biom15010046","journal-title":"Biomolecules"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88725","article-title":"The therapeutic effects of semaglutide in congenital linear scleroderma","volume":"17","author":"Chen H","year":"2025","unstructured":"Chen H, Elhawi M, Tarbox M. The therapeutic effects of semaglutide in congenital linear scleroderma. Cureus. 2025, 17:e88725. 10.7759\/cureus.88725","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac107","article-title":"Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review","volume":"188","author":"Krajewski PK","year":"2023","unstructured":"Krajewski PK, Matusiak \u0141, Szepietowski JC. Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review. Br J Dermatol. 2023, 188:320-7. 10.1093\/bjd\/ljac107","journal-title":"Br J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076390","article-title":"The role of adipokines in the pathogenesis of psoriasis","volume":"24","author":"Kie\u0142bowski K","year":"2023","unstructured":"Kie\u0142bowski K, Bakinowska E, Ostrowski P, et al.. The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci. 2023, 24:10.3390\/ijms24076390","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197604012941401","article-title":"The syndromes of insulin resistance and acanthosis nigricans \u2014 insulin-receptor disorders in man","volume":"294","author":"Kahn CR","year":"1976","unstructured":"Kahn CR, Flier JS, Bar RS, et al.. The syndromes of insulin resistance and acanthosis nigricans \u2014 insulin-receptor disorders in man. N Engl J Med. 1976, 294:739-45. 10.1056\/NEJM197604012941401","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita J","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, et al.. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017, 76:377-90. 10.1016\/j.jaad.2016.07.064","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis","volume":"39","author":"Upala S","year":"2015","unstructured":"Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond. 2015, 39:1197-202.","journal-title":"Int J Obes (Lond"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi P","year":"2008","unstructured":"Gisondi P, Del Giglio M, Di Francesco V, et al.. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008, 88:1242-7. 10.3945\/ajcn.2008.26427","journal-title":"Am J Clin Nutr"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12735","article-title":"Diet and physical exercise in psoriasis: a randomized controlled trial","volume":"170","author":"Naldi L","year":"2014","unstructured":"Naldi L, Conti A, Cazzaniga S, et al.. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol. 2014, 170:634-42. 10.1111\/bjd.12735","journal-title":"Br J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study","volume":"149","author":"Jensen P","year":"2013","unstructured":"Jensen P, Zachariae C, Christensen R, et al.. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatol. 2013, 149:795-801. 10.1001\/jamadermatol.2013.722","journal-title":"JAMA Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh H","year":"2020","unstructured":"Kadouh H, Chedid V, Halawi H, et al.. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020, 105:1552-63. 10.1210\/clinem\/dgz140","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-022-00522-0","article-title":"Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases","volume":"36","author":"Bassi M","year":"2022","unstructured":"Bassi M, Singh S. Impact of obesity on response to biologic therapies in patients with inflammatory bowel diseases. BioDrugs. 2022, 36:197-203. 10.1007\/s40259-022-00522-0","journal-title":"BioDrugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04536-0","article-title":"Obesity alters pathology and treatment response in inflammatory disease","volume":"604","author":"Bapat SP","year":"2022","unstructured":"Bapat SP, Whitty C, Mowery CT, et al.. Obesity alters pathology and treatment response in inflammatory disease. Nature. 2022, 604:337-42. 10.1038\/s41586-022-04536-0","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.055","article-title":"Systemic associations of hidradenitis suppurativa","volume":"73","author":"Kohorst JJ","year":"2015","unstructured":"Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015, 73:S27-35. 10.1016\/j.jaad.2015.07.055","journal-title":"J Am Acad Dermatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae238","article-title":"Unravelling the complex pathogenesis of hidradenitis suppurativa","volume":"192","author":"Frew JW","year":"2025","unstructured":"Frew JW. Unravelling the complex pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2025, 192:i3-i14. 10.1093\/bjd\/ljae238","journal-title":"Br J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale F","year":"2019","unstructured":"Zatterale F, Longo M, Naderi J, et al.. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2019, 10:1607. 10.3389\/fphys.2019.01607","journal-title":"Front Physiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.13223","article-title":"Skin metabolism in obesity: a narrative review","volume":"32","author":"Zaccaron RP","year":"2024","unstructured":"Zaccaron RP, Mendes C, da Costa C, et al.. Skin metabolism in obesity: a narrative review. Wound Repair Regen. 2024, 32:1022-7. 10.1111\/wrr.13223","journal-title":"Wound Repair Regen"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3830","article-title":"Impact of bariatric surgery on hidradenitis suppurativa","volume":"101","author":"Canard C","year":"2021","unstructured":"Canard C, Diaz Cives A, Gaubil-Kaladjian I, et al.. Impact of bariatric surgery on hidradenitis suppurativa. Acta Derm Venereol. 2021, 101:adv00471. 10.2340\/00015555-3830","journal-title":"Acta Derm Venereol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14691","article-title":"Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review","volume":"59","author":"Choi F","year":"2020","unstructured":"Choi F, Lehmer L, Ekelem C, Mesinkovska NA. Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review. Int J Dermatol. 2020, 59:143-53. 10.1111\/ijd.14691","journal-title":"Int J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1800","article-title":"The influence of body weight on the prevalence and severity of hidradenitis suppurativa","volume":"94","author":"Kromann CB","year":"2014","unstructured":"Kromann CB, Ibler KS, Kristiansen VB, Jemec GB. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014, 94:553-7. 10.2340\/00015555-1800","journal-title":"Acta Derm Venereol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13732","article-title":"Post-bariatric surgery hidradenitis suppurativa: a new patient subset associated with malabsorption and micronutritional deficiencies","volume":"44","author":"Garcovich S","year":"2019","unstructured":"Garcovich S, De Simone C, Giovanardi G, et al.. Post-bariatric surgery hidradenitis suppurativa: a new patient subset associated with malabsorption and micronutritional deficiencies. Clin Exp Dermatol. 2019, 44:283-9. 10.1111\/ced.13732","journal-title":"Clin Exp Dermatol"},{"key":"ref42","article-title":"HAIR-AN syndrome: a multisystem challenge","volume":"63","author":"Elmer KB","year":"2001","unstructured":"Elmer KB, George RM. HAIR-AN syndrome: a multisystem challenge. Am Fam Physician. 2001, 63:2385-90.","journal-title":"Am Fam Physician"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2014.58","article-title":"Hyperinsulinaemic androgen excess in adolescent girls","volume":"10","author":"Ib\u00e1\u00f1ez L","year":"2014","unstructured":"Ib\u00e1\u00f1ez L, Ong KK, L\u00f3pez-Bermejo A, et al.. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol. 2014, 10:499-508. 10.1038\/nrendo.2014.58","journal-title":"Nat Rev Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158214","article-title":"Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review","volume":"25","author":"Szekeres Z","year":"2024","unstructured":"Szekeres Z, Nagy A, Jahner K, Szabados E. Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism-a narrative review. Int J Mol Sci. 2024, 25:10.3390\/ijms25158214","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/biolre\/ioad032","article-title":"Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020","volume":"108","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Lin Y, Li G, et al.. Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue\u2020. Biol Reprod. 2023, 108:945-59. 10.1093\/biolre\/ioad032","journal-title":"Biol Reprod"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108743","article-title":"Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials","volume":"38","author":"Xie W","year":"2024","unstructured":"Xie W, Hong Z, Li B, et al.. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials. J Diabetes Complications. 2024, 38:108743. 10.1016\/j.jdiacomp.2024.108743","journal-title":"J Diabetes Complications"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14894","article-title":"Insulin resistance in hidradenitis suppurativa: a case-control study","volume":"32","author":"Vilanova I","year":"2018","unstructured":"Vilanova I, Hern\u00e1ndez JL, Mata C, et al.. Insulin resistance in hidradenitis suppurativa: a case-control study. J Eur Acad Dermatol Venereol. 2018, 32:820-4. 10.1111\/jdv.14894","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-02018-4","article-title":"Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa","volume":"312","author":"Gonz\u00e1lez-L\u00f3pez MA","year":"2020","unstructured":"Gonz\u00e1lez-L\u00f3pez MA, Vilanova I, Ocejo-Vi\u00f1als G, et al.. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Arch Dermatol Res. 2020, 312:595-600. 10.1007\/s00403-019-02018-4","journal-title":"Arch Dermatol Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.01.004","article-title":"Patients with psoriasis are insulin resistant","volume":"72","author":"Gyldenl\u00f8ve M","year":"2015","unstructured":"Gyldenl\u00f8ve M, Storgaard H, Holst JJ, et al.. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015, 72:599-605. 10.1016\/j.jaad.2015.01.004","journal-title":"J Am Acad Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158098","article-title":"Metabolic syndrome and psoriasis: pivotal roles of chronic inflammation and gut microbiota","volume":"25","author":"Secchiero P","year":"2024","unstructured":"Secchiero P, Rimondi E, Marcuzzi A, et al.. Metabolic syndrome and psoriasis: pivotal roles of chronic inflammation and gut microbiota. Int J Mol Sci. 2024, 25:10.3390\/ijms25158098","journal-title":"Int J Mol Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03508.x","article-title":"Androgenetic alopecia and insulin resistance in young men","volume":"71","author":"Gonz\u00e1lez-Gonz\u00e1lez JG","year":"2009","unstructured":"Gonz\u00e1lez-Gonz\u00e1lez JG, Mancillas-Adame LG, Fern\u00e1ndez-Reyes M, et al.. Androgenetic alopecia and insulin resistance in young men. Clin Endocrinol (Oxf). 2009, 71:494-9. 10.1111\/j.1365-2265.2008.03508.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0444","article-title":"Stimulatory effect of insulin on 5alpha-reductase type 1 (SRD5A1) expression through an Akt-dependent pathway in ovarian granulosa cells","volume":"151","author":"Kayampilly PP","year":"2010","unstructured":"Kayampilly PP, Wanamaker BL, Stewart JA, et al.. Stimulatory effect of insulin on 5alpha-reductase type 1 (SRD5A1) expression through an Akt-dependent pathway in ovarian granulosa cells. Endocrinology. 2010, 151:5030-7. 10.1210\/en.2010-0444","journal-title":"Endocrinology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2165\/11537000-000000000-00000","article-title":"Acne keloidalis nuchae: another cutaneous symptom of metabolic syndrome, truncal obesity, and impending\/overt diabetes mellitus?","volume":"11","author":"Verma SB","year":"2010","unstructured":"Verma SB, Wollina U. Acne keloidalis nuchae: another cutaneous symptom of metabolic syndrome, truncal obesity, and impending\/overt diabetes mellitus?. Am J Clin Dermatol. 2010, 11:433-6. 10.2165\/11537000-000000000-00000","journal-title":"Am J Clin Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00541-z","article-title":"Acne keloidalis nuchae and the metabolic syndrome: a population-based study","volume":"21","author":"Kridin K","year":"2020","unstructured":"Kridin K, Solomon A, Tzur-Bitan D, et al.. Acne keloidalis nuchae and the metabolic syndrome: a population-based study. Am J Clin Dermatol. 2020, 21:733-9. 10.1007\/s40257-020-00541-z","journal-title":"Am J Clin Dermatol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti G","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, et al.. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022, 182:106320. 10.1016\/j.phrs.2022.106320","journal-title":"Pharmacol Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong CK","year":"2024","unstructured":"Wong CK, McLean BA, Baggio LL, et al.. Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metab. 2024, 36:130-143.e5. 10.1016\/j.cmet.2023.11.009","journal-title":"Cell Metab"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2024.0057","article-title":"Anti-inflammatory effects of glucagon-like peptide-1 receptor agonists via the neuroimmune axis","volume":"43","author":"Fang S","year":"2024","unstructured":"Fang S, Wong CK. Anti-inflammatory effects of glucagon-like peptide-1 receptor agonists via the neuroimmune axis. DNA Cell Biol. 2024, 43:267-70. 10.1089\/dna.2024.0057","journal-title":"DNA Cell Biol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2232-3","article-title":"Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis","volume":"54","author":"Hogan AE","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T, et al.. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011, 54:2745-54. 10.1007\/s00125-011-2232-3","journal-title":"Diabetologia"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK","volume":"107","author":"Yang J","year":"2019","unstructured":"Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol. 2019, 107:124-8. 10.1016\/j.yexmp.2019.01.014","journal-title":"Exp Mol Pathol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert M","year":"2014","unstructured":"Buysschaert M, Baeck M, Preumont V, et al.. Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study. Br J Dermatol. 2014, 171:155-61. 10.1111\/bjd.12886","journal-title":"Br J Dermatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14703","article-title":"The many faces of interleukin-17 in inflammatory skin diseases","volume":"175","author":"Speeckaert R","year":"2016","unstructured":"Speeckaert R, Lambert J, Grine L, et al.. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol. 2016, 175:892-901. 10.1111\/bjd.14703","journal-title":"Br J Dermatol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228436","article-title":"Cytokine pathways and investigational target therapies in hidradenitis suppurativa","volume":"21","author":"Del Duca E","year":"2020","unstructured":"Del Duca E, Morelli P, Bennardo L, et al.. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020, 21:10.3390\/ijms21228436","journal-title":"Int J Mol Sci"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1593253","article-title":"The impact of innate immunity and epigenetics in the pathogenesis of hidradenitis suppurativa","volume":"16","author":"Burke OM","year":"2025","unstructured":"Burke OM, Frerichs VR, Garcia DF, et al.. The impact of innate immunity and epigenetics in the pathogenesis of hidradenitis suppurativa. Front Immunol. 2025, 16:1593253. 10.3389\/fimmu.2025.1593253","journal-title":"Front Immunol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0396-5","article-title":"Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes","volume":"67","author":"Marx N","year":"2010","unstructured":"Marx N, Burgmaier M, Heinz P, et al.. Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci. 2010, 67:3549-55. 10.1007\/s00018-010-0396-5","journal-title":"Cell Mol Life Sci"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114050","article-title":"Pro-healing impact of liraglutide on skin wounds in normoglycemic mice","volume":"147","author":"Yue H","year":"2025","unstructured":"Yue H, Zhang X, Zhao Z, et al.. Pro-healing impact of liraglutide on skin wounds in normoglycemic mice. Int Immunopharmacol. 2025, 147:114050. 10.1016\/j.intimp.2025.114050","journal-title":"Int Immunopharmacol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405987","article-title":"Liraglutide promotes diabetic wound healing via Myo1c\/Dock5","volume":"11","author":"Zhang Q","year":"2024","unstructured":"Zhang Q, Zhang C, Kang C, et al.. Liraglutide promotes diabetic wound healing via Myo1c\/Dock5. Adv Sci (Weinh). 2024, 11:e2405987. 10.1002\/advs.202405987","journal-title":"Adv Sci (Weinh)"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae K","year":"2018","unstructured":"Nagae K, Uchi H, Morino-Koga S, et al.. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018, 146:155-61. 10.1016\/j.diabres.2018.10.013","journal-title":"Diabetes Res Clin Pract"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1159\/000071783","article-title":"Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma","volume":"207","author":"Hasegawa M","year":"2003","unstructured":"Hasegawa M, Sato S, Nagaoka T, et al.. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology. 2003, 207:141-7. 10.1159\/000071783","journal-title":"Dermatology"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810134","article-title":"Interferon-gamma-inducible protein-10 (IP-10) and tumor necrosis factor-\u03b1 (TNF-\u03b1) as serological predictors of active disease status in localized scleroderma","volume":"25","author":"Ashe B","year":"2024","unstructured":"Ashe B, Zigler CK, Yabes J, et al.. Interferon-gamma-inducible protein-10 (IP-10) and tumor necrosis factor-\u03b1 (TNF-\u03b1) as serological predictors of active disease status in localized scleroderma. Int J Mol Sci. 2024, 25:10.3390\/ijms251810134","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06127-w","article-title":"Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma","volume":"41","author":"Zhu X","year":"2022","unstructured":"Zhu X, Jiang L, Zhong Q, et al.. Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma. Clin Rheumatol. 2022, 41:2179-87. 10.1007\/s10067-022-06127-w","journal-title":"Clin Rheumatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2924","article-title":"Inflammasome activation characterizes lesional skin of folliculitis decalvans","volume":"98","author":"Eyraud A","year":"2018","unstructured":"Eyraud A, Milpied B, Thiolat D, et al.. Inflammasome activation characterizes lesional skin of folliculitis decalvans. Acta Derm Venereol. 2018, 98:570-5. 10.2340\/00015555-2924","journal-title":"Acta Derm Venereol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03352-y","article-title":"The role of IL-17 and Th17 cells in keloid pathogenesis","volume":"316","author":"Bitterman D","year":"2024","unstructured":"Bitterman D, Wang JY, Collins A, et al.. The role of IL-17 and Th17 cells in keloid pathogenesis. Arch Dermatol Res. 2024, 316:626. 10.1007\/s00403-024-03352-y","journal-title":"Arch Dermatol Res"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou A","year":"2013","unstructured":"Faurschou A, Pedersen J, Gyldenl\u00f8ve M, et al.. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013, 22:150-2. 10.1111\/exd.12081","journal-title":"Exp Dermatol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/cells11162587","article-title":"Induced human regulatory T cells express the glucagon-like peptide-1 receptor","volume":"11","author":"Rode AK","year":"2022","unstructured":"Rode AK, Buus TB, Mraz V, et al.. Induced human regulatory T cells express the glucagon-like peptide-1 receptor. Cells. 2022, 11:10.3390\/cells11162587","journal-title":"Cells"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4918-x","article-title":"Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes","volume":"62","author":"Aung MM","year":"2019","unstructured":"Aung MM, Slade K, Freeman LA, et al.. Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes. Diabetologia. 2019, 62:1701-11. 10.1007\/s00125-019-4918-x","journal-title":"Diabetologia"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar CE","year":"2024","unstructured":"Salazar CE, Patil MK, Aihie O, et al.. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024, 316:248. 10.1007\/s00403-024-02969-3","journal-title":"Arch Dermatol Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404845-use-of-glucagon-like-peptide-1-glp-1-agonists-in-modulating-preexisting-dermatologic-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:57:31Z","timestamp":1758895051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404845-use-of-glucagon-like-peptide-1-glp-1-agonists-in-modulating-preexisting-dermatologic-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":76,"URL":"https:\/\/doi.org\/10.7759\/cureus.93282","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}